Mi az ára Decibel Therapeutics, Inc. (DBTX)

Decibel Therapeutics, Inc. (DBTX) ára $4.91

Mi a Decibel Therapeutics, Inc. (DBTX piaci tőkésítése)

Decibel Therapeutics, Inc. piaci tőkésítése (DBTX) $36.12M

Decibel Therapeutics, Inc. (DBTX) Forgalomban Lévő Részvények

Decibel Therapeutics, Inc. (DBTX) is a clinical-stage biotechnology firm dedicated to pioneering innovative therapies for a range of hearing and balance impairments. Their research and development efforts are concentrated across three primary therapeutic avenues: 1. Gene Therapies for Congenital, Monogenic Hearing Loss: These programs aim to re-establish functional cellular activity within the cochlea, thereby counteracting hearing deficiencies stemming from single gene mutations. 2. Gene Therapies for Hair Cell Regeneration: This pipeline focuses on replenishing lost hair cells in the inner ear to alleviate acquired hearing and balance conditions. 3. Otoprotection Therapeutic: Currently in clinical development, this therapeutic is designed to safeguard cancer patients from hearing loss induced by cisplatin chemotherapy. A flagship gene therapy candidate, DB-OTO, is being developed to restore auditory function in individuals suffering from profound hearing loss linked to mutations in the otoferlin gene. The company is also advancing several other programs, including DB-ATO and AAV.201, gene therapies intended to regenerate lost vestibular hair cells and thus re-establish balance in patients with bilateral vestibulopathy. DB-020 is undergoing Phase 1b clinical trials for the prevention of hearing loss caused by cisplatin. Further gene therapies in development include AAV.103 for individuals with a gap junction beta-2 (GJB2) deficiency, AAV.104 for those with a stereocilin (STRC) deficiency, and a cochlear hair cell regeneration program that employs AAV-based gene therapy to convert supporting cells into functional outer hair cells using cell-selective reprogramming factors. Decibel Therapeutics maintains a strategic alliance with Regeneron Pharmaceuticals, Inc., specifically for co-developing gene therapies addressing monogenic forms of inherited hearing loss. Established in 2013 and initially known as Hearing Inc., the company rebranded as Decibel Therapeutics, Inc. in April 2014. Its operations are headquartered in Boston, Massachusetts.

Év	Kintlévő részvények	Változtassa meg
2026 (TTM)	103.40M	-1.15%
2025	104.60M	-3.06%
2024	107.90M	1.12%
2023	106.70M	-0.37%
2022	107.10M	1.32%
2021	105.70M	-1.77%
2020	107.60M	-1.47%
2019	109.20M	-4.88%
2018	114.80M	-0.95%
2017	115.90M	-0.30%
2016	116.25M	0.89%
2015	115.23M	1.60%
2014	113.41M	1.97%
2013	111.22M	0.13%
2012	111.07M	22.58%
2011	90.61M	9.27%
2010	82.93M	3.94%
2009	79.78M	1.21%
2008	78.83M	18.83%
2007	66.33M	14.43%
2006	57.97M	3.61%
2005	55.95M	0.96%
2004	55.42M	9.85%
2003	50.45M	14.79%
2002	43.95M	4.42%
2001	42.09M	19.66%
2000	35.17M	0.00%

Év

Kintlévő részvények

Változtassa meg

2026 (TTM)

103.40M

-1.15%

2025

104.60M

-3.06%

2024

107.90M

1.12%

2023

106.70M

-0.37%

2022

107.10M

1.32%

2021

105.70M

-1.77%

2020

107.60M

-1.47%

2019

109.20M

-4.88%

2018

114.80M

-0.95%

2017

115.90M

-0.30%

2016

116.25M

0.89%

2015

115.23M

1.60%

2014

113.41M

1.97%

2013

111.22M

0.13%

2012

111.07M

22.58%

2011

90.61M

9.27%

2010

82.93M

3.94%

2009

79.78M

1.21%

2008

78.83M

18.83%

2007

66.33M

14.43%

2006

57.97M

3.61%

2005

55.95M

0.96%

2004

55.42M

9.85%

2003

50.45M

14.79%

2002

43.95M

4.42%

2001

42.09M

19.66%

2000

35.17M

0.00%

Vállalat	Kintlévő részvények	Különbség	Ország
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	145.55%	US
Moderna, Inc. MRNA.US	396.00M	282.98%	US
Argenx SE ARGX.US	62.19M	-39.86%	NL
CSL Limited CSL.AX	478.91M	363.16%	AU
Lonza Group AG LONN.SW	-	-	CH

Vállalat

Kintlévő részvények

Különbség

Ország